Trials / Recruiting
RecruitingNCT06980012
Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.
Evaluation of the Impact of the Clinical Pharmacist in the Initiation and Follow-up of Oral Therapies in Oncology.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Polyclinique Lyon Nord · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management.. The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring. The primary endpoint is compliance with the Girerd questionnaire.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pharmaceutical consultation | The pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment. |
| PROCEDURE | Pharmaceutical consultation and follow-up | After the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book. |
Timeline
- Start date
- 2024-12-31
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
- First posted
- 2025-05-20
- Last updated
- 2025-08-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06980012. Inclusion in this directory is not an endorsement.